Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00133107 · ClinicalTrials.gov registry record · NA
Safety and Effectiveness of Efalizumab to Treat Oral Lichen Planus
A NA study of Lichen Planus, Oral, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- NA
- Development phase
- 4
- Enrollment target
- 1
- Study location
NCT00133107 is a NA study of Lichen Planus, Oral that has completed, run by Washington University School of Medicine. The registered enrollment target is 4 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00133107, a NA study of Lichen Planus, Oral, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- NA
- Development phase
- 4 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is to determine whether efalizumab 1.0mg/kg given by subcutaneous injection for 12 weeks is effective in treating oral lichen planus. This is a 20 week, single center, open-label pilot study to enroll 5 subjects.
Conditions Studied
Interventions
- DRUG efalizumab
Study Locations (1)
Missouri
- Washington University - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2005-01 |
| Est. Completion | 2005-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00133107
The ClinicalTrials.gov registry entry for NCT00133107 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lichen Planus, Oral appearing as the primary indexed condition, and to 1 intervention - of which efalizumab is the first listed.
NCT00133107 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT00133107 about?
NCT00133107 is a clinical study titled "Safety and Effectiveness of Efalizumab to Treat Oral Lichen Planus". This study is to determine whether efalizumab 1.0mg/kg given by subcutaneous injection for 12 weeks is effective in treating oral lichen planus. This is a 20 week, single center, open-label pilot study to enroll 5 subjects.
What is the current status of trial NCT00133107?
This trial is currently completed. It is a NA study. The enrollment target is 4 participants. The study started on 2005-01. Estimated completion is 2005-11.
What conditions does trial NCT00133107 study?
This clinical trial studies the following conditions: Lichen Planus, Oral.
What interventions are being tested in trial NCT00133107?
The interventions under investigation include: efalizumab (DRUG).
Who is sponsoring clinical trial NCT00133107?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00133107 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lichen Planus, Oral
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.